Adocia Logo

Adocia

ADOC | PA

Overview

Corporate Details

ISIN(s):
FR0011184241 (+1 more)
LEI:
969500ZL79KYH9PTYP78
Country:
France
Address:
115 AVENUE LACASSAGNE, 69003 LYON
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Adocia is a clinical-stage biotechnology company founded in 2005, specializing in the development of innovative treatments for metabolic diseases, primarily diabetes and obesity. The company leverages its proprietary technology platforms and strong intellectual property to create best-in-class therapies by developing novel formulations of already-approved peptides and proteins, including insulins and other metabolic hormones. Adocia's product pipeline ranges from these advanced formulations to immunoprotective scaffolds for cell therapies. Its business model focuses on out-licensing its products and technologies to partners after establishing clinical proof-of-concept in humans.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Adocia. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-02 10:34
Regulatory News Service
Déclaration d'intention (FS 225C1435)
French 130.2 KB
2025-09-02 10:30
Regulatory News Service
Franchissement de seuil
French 111.8 KB
2025-07-11 11:18
Major Shareholding Notification
Franchissements de seuil
French 116.2 KB
2025-06-12 18:00
Declaration of Voting Results & Voting Rights Announcements
Inside Information / Other news releases
English 492.1 KB
2025-06-12 18:00
Declaration of Voting Results & Voting Rights Announcements
Informations privilégiées / Autres communiqués
French 491.7 KB
2025-05-22 18:00
Regulatory News Service
Inside Information / Other news releases
English 452.1 KB
2025-05-22 18:00
Regulatory News Service
Informations privilégiées / Autres communiqués
French 472.2 KB
2025-05-21 18:00
Pre-Annual General Meeting Information
Informations privilégiées / Autres communiqués
French 120.9 KB
2025-05-21 18:00
Pre-Annual General Meeting Information
Inside Information / Other news releases
English 130.5 KB
2025-05-15 18:00
Declaration of Voting Results & Voting Rights Announcements
Inside Information / Other news releases
English 474.1 KB
2025-05-15 18:00
Declaration of Voting Results & Voting Rights Announcements
Informations privilégiées / Autres communiqués
French 473.1 KB
2025-05-14 18:00
Earnings Release
Inside Information / News release on accounts, results
English 576.9 KB
2025-05-14 18:00
Earnings Release
Informations privilégiées / Communiqué sur comptes, résultats
French 531.5 KB
2025-04-30 18:00
Registration Form
Inside Information / Other news releases
English 473.1 KB
2025-04-30 18:00
Registration Form
Informations privilégiées / Autres communiqués
French 461.0 KB

Automate Your Workflow. Get a real-time feed of all Adocia filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Adocia via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-03-21 N/A Other Buy 51,921 499,999.23 EUR
2024-03-21 N/A Other Buy 15,576 149,996.88 EUR
2023-12-29 N/A Other Sell 20,000 236,550.00 EUR
2023-10-05 N/A Other Sell 50,000 400,000.00 EUR
2023-09-20 N/A Other Sell 36,240 291,376.85 EUR
2023-07-28 N/A Other Buy 220,264 999,998.56 EUR
2023-07-28 N/A Other Buy 110 499.40 EUR

Peer Companies

Company Country Ticker View
THERACRYF PLC Logo
Developing sulforaphane-based therapeutics for oncology and behavioural brain disorders.
United Kingdom TCF
Theranexus Logo
Biopharma developing drug candidates for rare neurological diseases like Batten disease.
France ALTHX
TME Pharma N.V. Logo
Clinical-stage biotech developing TME-targeting therapies for aggressive cancers.
Germany ALTME
Toleranzia AB Logo
Developing immune therapies for rare autoimmune diseases like myasthenia gravis.
Sweden TOL
Transgene Logo
Clinical-stage biotech using viral vectors for cancer vaccines and oncolytic viruses.
France TNG
Tvardi Therapeutics Inc. Logo United States of America TVRD
UCAR Logo
A nonprofit consortium managing atmospheric research and providing resources to the scientific community.
France ALUCR
Hong Kong N/A
Urteste S.A. Logo
Developing non-invasive urine tests for early detection & monitoring of multiple cancers.
Poland URT
VALIRX PLC Logo
Developing early-stage therapeutics & diagnostics for oncology and women's health.
United Kingdom VAL